1.
Mertins P, Tang LC, Krug K, et al. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. Nat Protoc. 2018;13(7):1632-1661. doi:10.1038/s41596-018-0006-9.
1.
Golfmann K, Meder L, Koker M, et al. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018;37(42):5682-5693. doi:10.1038/s41388-018-0380-3.
1.
Farahany NA, Greely HT, Hyman S, et al. The ethics of experimenting with human brain tissue. Nature. 2018;556(7702):429-432. doi:10.1038/d41586-018-04813-x.
1.
Fiorini C, Abdulhay NJ, McFarland SK, et al. Developmentally-faithful and effective human erythropoiesis in immunodeficient and Kit mutant mice. Am J Hematol. 2017;92(9):E513-E519. doi:10.1002/ajh.24805.
1.
Ben-David U, Ha G, Tseng Y-Y, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017;49(11):1567-1575. doi:10.1038/ng.3967.
1.
Haidet-Phillips AM, Roybon L, Gross SK, et al. Gene profiling of human induced pluripotent stem cell-derived astrocyte progenitors following spinal cord engraftment. Stem Cells Transl Med. 2014;3(5):575-85. doi:10.5966/sctm.2013-0153.
1.
Zhou J-Y, Chen L, Zhang B, et al. Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues. J Proteome Res. 2017;16(12):4523-4530. doi:10.1021/acs.jproteome.7b00362.
1.
McPherson AW, Roth A, Ha G, et al. ReMixT: clone-specific genomic structure estimation in cancer. Genome Biol. 2017;18(1):140. doi:10.1186/s13059-017-1267-2.
1.
Dudani JS, Ibrahim M, Kirkpatrick J, Warren AD, Bhatia SN. Classification of prostate cancer using a protease activity nanosensor library. Proc Natl Acad Sci U S A. 2018;115(36):8954-8959. doi:10.1073/pnas.1805337115.
1.
Shen RR, Zhou AY, Kim E, et al. TRAF2 is an NF-κB-activating oncogene in epithelial cancers. Oncogene. 2015;34(2):209-16. doi:10.1038/onc.2013.543.